Effects of macrophage-specific adiponectin expression on lipid metabolism in vivo

American Journal of Physiology - Endocrinology and Metabolism

Volumn 301, Issue 1, 2011, Pages

  Luo, Nanlan ^a   Wang, Xiangdong ^c   Chung, B Hong ^a   Lee, Mi Hye ^d   Klein, Richard L ^d   Garvey, W Timothy ^a,b   Fu, Yuchang ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Atherosclerosis; Metabolic disorder; Type 2 diabetes

Indexed keywords

ABC TRANSPORTER G1; ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ENGINEERING; GLUCOSE METABOLISM; INFLAMMATION; LIPID METABOLISM; LIVER; MACROPHAGE; MOLECULAR MECHANICS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; WILD TYPE;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION REGULATION; GLUCOSE; INFLAMMATION; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; LIVER; MACROPHAGES, PERITONEAL; MICE; MICE, TRANSGENIC; ORGAN SPECIFICITY;

EID: 79959603581     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00614.2010     Document Type: Article

References (46)

1. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28: 1225-1236, 2008.
2. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
3. Bauche IB, El Mkadem SA, Pottier AM, Senou M, Many MC, Rezsohazy R, Penicaud L, Maeda N, Funahashi T, Brichard SM. Overexpression of adiponectin targeted to adipose tissue in transgenic mice: impaired adipocyte differentiation. Endocrinology 148: 1539-1549, 2007.
4. Bouloumie A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 8: 347-354, 2005.
5. Breslow JL. Familial disorders of high-density lipoprotein metabolism. In: The Metabolic and Molecular Bases of Inherited Disease, 7th Ed., edited by Scriver CR, Beaudet AL, Sly WS, and Valle D. New York: McGraw-Hill, 1995, p. 2031-2052.
6. Chan DC, Barrett PH, Watts GF. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol 17: 28-36, 2006.
7. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 1: 510-514, 2000.
8. Chung BH, Segrest JP, Pfau J, Cone JT, Geer JC, Duncan LA. High resolution plasma lipoprotein cholesterol profiles by a rapid high volume automated method. J Lipid Res 22: 1003-1014, 1981.
9. Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin density gradient ultracentrifugation. Method Enzymol 128: 181-212, 1986.
10. Cottrell DA, Marshall BJ, Falko JM. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Curr Opin Cardiol 18: 301-308, 2003.
11. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 36: 211-228, 1995.
12. Franceschini G. Apolipoprotein function in health and disease: insights from natural mutations. Eur J Clin Invest 26: 733-746, 1996.
13. Furukawa K, Hori M, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Miyazaki A, Nakayama H, Horiuchi S. Adiponectin down-regulates acyl-coenzyme A: cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 317: 831-836, 2004.
14. Ginsberg HN, Stalenhoef AFH. The metabolic syndromes: targeting dyslipidemia to reduce coronary risk. J Cardiovasc Risk 10: 121-128, 2003.
15. Hulthe J, Hultén LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 52: 1612-1614, 2003.
16. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893, 1993.
17. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494-1505, 2006.
18. Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 53: 589-593, 2004.
19. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 83: 137-142, 1989.
20. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863-25866, 2002.
21. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 18: 263-270, 2007.
22. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-58, 2002.
23. Lindsay RS, Funahashi T, Krakoff J, Matsuzawa Y, Tanaka S, Kobes S, Bennett PH, Tataranni PA, Knowler WC, Hanson RL. Genomewide linkage analysis of serum adiponectin in the Pima Indian population. Diabetes 52: 2419-2425, 2003.
24. Linton MF, Gish R, Hubl ST, Butler E, Esquivel C, Bry WI, Boyles JK, Wardell MR, Young SG. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 88: 270-281, 1991.
25. Liuab Y, Lia D, Chena J, Xiea J, Bandyopadhyaya S, Zhangac D, Nemarkommulaa AR, Liua H, Mehtaa JL, Hermonatab PL. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adenoassociated virus type 2-hIL-10. Atherosclerosis 188: 19-27, 2006.
26. Luo N, Liu J, Chung BH, Yang QL, Klein RL, Garvey WT, Fu Y. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 59: 791-799, 2010.
27. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 25: 1277-1294, 1984.
28. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 23: 344-346, 2005.
29. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, Sugiura K, Kondo T, Murohara T, Toyoshima H. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26: 871-876, 2006.
30. Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Maeda N, Tsujii K, Ishigami M, Nishida M, Hirano K, Kihara S, Hori M, Shimomura I, Yamashita S. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 358: 1091-1095, 2007.
31. Neumeier M, Sigruener A, Eggenhofer E, Weigert J, Weiss TS, Schaeffler A, Schlitt HJ, Aslanidis C, Piso P, Langmann T, Schmitz G, Schölmerich J, Buechler C. High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem Biophys Res Comm 352: 543-548, 2007.
32. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 54: 795-802, 2005.
33. Nye C, Kim J, Kalhan SC, Hanson RW. Reassessing triglyceride synthesis in adipose tissue. Trends Endocrinol Metab 19: 356-361, 2008.
34. Okada T, Saito E, Kuromori Y, Miyashita M, Iwata F, Hara M, Harada K. Relationship between serum adiponectin level and lipid composition in each lipoprotein fraction in adolescent children. Atherosclerosis 188: 179-183, 2006.
35. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages. Circulation 103: 1057-1063, 2001.
36. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14: 561-566, 2003.
37. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152-12162, 2004.
38. Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 57: 1824-1833, 2008.
39. Reshef L, Olswang Y, Cassuto H, Blum B, Croniger CM, Kalhan SC, Tilghman SM, Hanson RW. Glyceroneogenesis and the triglyceride/fatty acid cycle. J Biol Chem 278: 30413-30416, 2003.
40. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749, 1995.
41. Terasaka N, Yu S, Yvan-Charvet L, Wang N, Mzhavia N, Langlois R, Pagler T, Li R, Welch CL, Goldberg IJ, Tall AR. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 118: 3701-3713, 2008.
42. Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 202: 152-161, 2009.
43. Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem 280: 30150-30157, 2005.
44. Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 26: 1364-1369, 2006.
45. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
46. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.